Corton Capital Inc. Prothena Corp Public LTD CO Transaction History

Corton Capital Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $73,788 - $110,135	1,560 Added 20.71%	9,091 $438,000
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $151,005 - $245,908	3,129 Added 71.08%	7,531 $514,000
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $206,761 - $256,504	4,402 New	4,402 $213,000
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $434,435 - $706,405	-14,352 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $604,362 - $1.05 Million	14,352 New	14,352 $709,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.